Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease

International Journal of Molecular Medicine

Volumn 30, Issue 1, 2012, Pages 49-56

  De Vito, Rita ^a   Alisi, Anna ^a   Masotti, Andrea ^a   Ceccarelli, Sara ^a   Panera, Nadia ^a   Citti, Arianna ^a   Salata, Michele ^a   Valenti, Luca ^b   Feldstein, Ariel E ^c   Nobili, Valerio ^a,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

CD163; CD3; CD45; Children; Kupffer cells; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

CD163 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN;

ADOLESCENT; ARTICLE; CELL COUNT; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KUPFFER CELL; LEUKOCYTE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; MALE; NONALCOHOLIC FATTY LIVER; PORTAL VEIN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEATOSIS; T LYMPHOCYTE;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CHILD; FATTY LIVER; FEMALE; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MALE; NATURAL KILLER T-CELLS; OBESITY; RECEPTORS, CELL SURFACE;

EID: 84861467791     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.965     Document Type: Article

References (54)

1. Alisi A, Manco M, Vania A and Nobili V: Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 155: 469-474, 2009.
2. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB and Angulo P: The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58: 1538-1544, 2009.
3. Papandreou D, Rousso I and Mavromichalis I: Update on non-alcoholic fatty liver disease in children. Clin Nutr 26: 409-415, 2007. (Pubitemid 47091479)
4. Dunn W and Schwimmer JB: The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 10: 67-72, 2008.
5. Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16, 2001.
6. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D and Molleston J: Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135: 1961-1971, 2008.
7. Kim CH and Younossi ZM: Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75: 721-728, 2008.
8. Pardee PE, Lavine JE and Schwimmer JB: Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 18: 144-151, 2009.
9. Nobili V, Alisi A and Raponi M: Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 15: 6017-6022, 2009.
10. de Alwis NM and Day CP: Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 (Suppl 1): S104-S112, 2008.
11. Alisi A, Locatelli M and Nobili V: Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 13: 397-402, 2010.
12. Feldstein AE: Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30: 391-401, 2010.
13. Tilg H and Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19: 371-379, 2008.
14. Baffy G: Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51: 212-223, 2009.
15. Park JW, Jeong G, Kim SJ, Kim MK and Park SM: Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 22: 491-497, 2007. (Pubitemid 46434984)
16. Fotiadu A, Gagalis A, Akriviadis E, Kotoula V, Sinakos E, Karkavelas G and Hytiroglou P: Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int 60: 87-92, 2010.
17. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M and Wallace M: Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47: 571-579, 2007. (Pubitemid 47331747)
18. Bilzer M, Roggel F and Gerbes AL: Role of Kupffer cells in host defense and liver disease. Liver Int 26: 1175-1186, 2006. (Pubitemid 44741204)
19. Kolios G, Valatas V and Kouroumalis E: Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 12: 7413-7420, 2006. (Pubitemid 46017736)
20. Zhan YT and An W: Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 16: 4652-4660, 2010.
21. Kremer M and Hines IN: Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J Gastroenterol 14: 487-488, 2008. (Pubitemid 351320862)
22. Alisi A, Panera N and Nobili V: The link between hepatosteatosis and cells of the immune system. Hepatology 51: 1472-1473, 2010.
23. Alisi A, Panera N and Nobili V: Toll-like receptor 4: a starting point for proinflammatory signals in fatty liver disease. Hepatology 51: 714-715, 2010.
24. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC and Bergheim I: Toll-like receptor 4 is involved in the development of fructose induced hepatic steatosis in mice. Hepatology 50: 1094-1104, 2009.
25. Kremer M, Thomas E, Milton RJ, et al: Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 51: 130-141, 2010.
26. Stienstra R, Saudale F, Duval C, et al: Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 51: 511-522, 2010.
27. Torlakovic EE, Naresh K, Kremer M, van der Walt J, Hyjek E and Porwit A: Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study. J Clin Pathol 62: 547-551, 2009.
28. Fabriek BO, Dijkstra CD and van den Berg TK: The macrophage scavenger receptor CD163. Immunobiology 210: 153-160, 2005. (Pubitemid 41025156)
29. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA and Natkunam Y: Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 29: 617-624, 2005. (Pubitemid 40577871)
30. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al: CDC growth charts: United States. Adv Data 314: 1-27, 2000.
31. Matsuda M and DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999. (Pubitemid 29418240)
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985. (Pubitemid 15018832)
33. Kleiner DE, Brunt EM, Van Natta M, et al: Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005. (Pubitemid 40770284)
34. Alisi A, Bedogni G, De Vito R, Comparcola D, Manco M and Nobili V: Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. Dig Liver Dis 43: 143-146, 2011.
35. Valenti L, Fracanzani AL and Fargion S: The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol 31: 359-369, 2009.
36. Li Z, Soloski MJ and Diehl AM: Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42: 880-885, 2005. (Pubitemid 41401126)
37. de Luca C and Olefsky JM: Inflammation and insulin resistance. FEBS Lett 582: 97-105, 2008. (Pubitemid 50010731)
38. Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R and Li Z: A high fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46: 1519-1529, 2007. (Pubitemid 350155534)
39. Shoelson SE, Herrero L and Naaz A: Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169-2180, 2007. (Pubitemid 46693756)
40. + natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 21: 673-680, 2009.
41. Notas G, Kisseleva T and Brenner D: NK and NKT cells in liver injury and fibrosis. Clin Immunol 130: 16-26, 2009.
42. + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50: 261-274, 2009.
43. Alisi A, Da Sacco L, Bruscalupi G, et al: Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 91: 283-293, 2011.
44. Holland-Fischer P, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, et al: Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 60: 1389-1393, 2011.
45. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, et al: Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance inchronic HCV infection. Gastroenterology 133: 1627-1636, 2007. (Pubitemid 350029734)
46. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T and Onji M: Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract 201: 379-384, 2005. (Pubitemid 40862463)
47. Bauer S, Weiss TS, Wiest R, Schacherer D, Hellerbrand C, Farkas S, Scherer MN, et al: Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro. Exp Mol Pathol 91: 733-739, 2011.
48. Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN and Guyre PM: Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 80: 26-35, 2006. (Pubitemid 44835523)
49. Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U and Diehl AM: Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 31: 633-640, 2000. (Pubitemid 30118631)
50. Kremer M, Hines IN, Milton RJ and Wheeler MD: Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 44: 216-227, 2006. (Pubitemid 44049154)
51. Xu CF, Yu CH, Li YM, Xu L, Du J and Shen Z: Association of the frequency of peripheral natural killer T cells with nonalcoholic fatty liver disease. World J Gastroenterol 13: 4504-4508, 2007. (Pubitemid 47412416)
52. Eberl G and MacDonald HR: Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 9: 345-353, 1998. (Pubitemid 28462755)
53. Miyagi T, Takehara T, Uemura A, et al: Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. J Gastroenterol 45: 1247-1254, 2010.
54. Iacono A, Raso GM, Canani RB, Calignano A and Meli R: Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 22: 699-711, 2011.